Alhadeff J A, Prorok J J, Dura P A, Plucinsky M C, Beesburg R Y
Cancer Res. 1984 Nov;44(11):5422-6.
Previous studies have reported altered isozyme compositions and properties of beta-hexosaminidase in human cancerous tissues, and an atypical beta-hexosaminidase was found previously in metastatic tumor tissue of human liver. The present investigation was concerned with determining if this atypical beta-hexosaminidase could be detected (by analytical column isoelectric focusing) in the sera of cancer patients who have liver metastases. Analyses of sera from 14 cancer patients indicated that 12 contained an atypical beta-hexosaminidase in addition to normal beta-hexosaminidase A and B. Analysis of sera from 15 normal controls and 8 controls with benign disease indicated that the atypical beta-hexosaminidase may be specific for malignant disease. The mean percentage of recovered beta-hexosaminidase activity associated with peaks of beta-hexosaminidase B (i.e., peaks with isoelectric point values at or near that of normal beta-hexosaminidase B) was slightly elevated in cancer sera [37 +/- 9.6% (S.D.)] when compared to normal (32 +/- 9%) and pathological control (29 +/- 10%) sera. The variant beta-hexosaminidase may prove to be a useful general marker for tumor burden or a more specific marker for liver metastases.
以往的研究报道了人类癌组织中β-己糖胺酶同工酶组成和性质的改变，并且此前在人类肝脏转移瘤组织中发现了一种非典型β-己糖胺酶。本研究旨在确定在有肝转移的癌症患者血清中是否能检测到这种非典型β-己糖胺酶（通过分析柱等电聚焦法）。对14例癌症患者的血清分析表明，除了正常的β-己糖胺酶A和B外，其中12例含有非典型β-己糖胺酶。对15例正常对照和8例良性疾病对照的血清分析表明，非典型β-己糖胺酶可能对恶性疾病具有特异性。与正常血清[32±9%]和病理对照血清[29±10%]相比，癌症血清中与β-己糖胺酶B峰（即等电点值与正常β-己糖胺酶B相同或相近的峰）相关的β-己糖胺酶活性回收平均百分比略有升高[37±9.6%（标准差）]。这种变异的β-己糖胺酶可能被证明是肿瘤负荷的一种有用的通用标志物，或者是肝转移的一种更具特异性的标志物。
